<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7279248</article-id><article-id pub-id-type="doi">10.3390/ijms21103622</article-id><article-id pub-id-type="publisher-id">ijms-21-03622</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Longhitano</surname><given-names>Lucia</given-names></name><xref ref-type="aff" rid="af1-ijms-21-03622">1</xref><xref ref-type="author-notes" rid="fn1-ijms-21-03622">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4416-8556</contrib-id><name><surname>Tibullo</surname><given-names>Daniele</given-names></name><xref ref-type="aff" rid="af1-ijms-21-03622">1</xref><xref ref-type="author-notes" rid="fn1-ijms-21-03622">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Giallongo</surname><given-names>Cesarina</given-names></name><xref ref-type="aff" rid="af2-ijms-21-03622">2</xref><xref rid="c1-ijms-21-03622" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Lazzarino</surname><given-names>Giacomo</given-names></name><xref ref-type="aff" rid="af3-ijms-21-03622">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6845-7080</contrib-id><name><surname>Tartaglia</surname><given-names>Nicola</given-names></name><xref ref-type="aff" rid="af4-ijms-21-03622">4</xref></contrib><contrib contrib-type="author"><name><surname>Galimberti</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="af5-ijms-21-03622">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8678-2183</contrib-id><name><surname>Li Volti</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="af1-ijms-21-03622">1</xref><xref rid="c1-ijms-21-03622" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1859-6319</contrib-id><name><surname>Palumbo</surname><given-names>Giuseppe Alberto</given-names></name><xref ref-type="aff" rid="af2-ijms-21-03622">2</xref><xref ref-type="author-notes" rid="fn2-ijms-21-03622">&#x02021;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5638-227X</contrib-id><name><surname>Liso</surname><given-names>Arcangelo</given-names></name><xref ref-type="aff" rid="af4-ijms-21-03622">4</xref><xref ref-type="author-notes" rid="fn2-ijms-21-03622">&#x02021;</xref></contrib></contrib-group><aff id="af1-ijms-21-03622"><label>1</label>Section of Biochemistry, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy; <email>lucia.longhitano@phd.unict.it</email> (L.L.); <email>d.tibullo@unict.it</email> (D.T.)</aff><aff id="af2-ijms-21-03622"><label>2</label>Section of Haematology, Department of Scienze Mediche Chirurgiche e Tecnologie Avanzate &#x0201c;G.F. Ingrassia&#x0201d;, University of Catania, 95123 Catania, Italy; <email>giuseppealberto.palumbo@gmail.com</email></aff><aff id="af3-ijms-21-03622"><label>3</label>UniCamillus&#x02014;Saint Camillus International University of Health Sciences, Via di Sant&#x02019;Alessandro 8, 00131 Rome, Italy; <email>giacomo.lazzarino@unicamillus.org</email></aff><aff id="af4-ijms-21-03622"><label>4</label>Department of Medical and Surgical Sciences, University of Foggia, 71100 Foggia, Italy; <email>nicola.tartaglia@unifg.it</email> (N.T.); <email>arcangelo.liso@unifg.it</email> (A.L.)</aff><aff id="af5-ijms-21-03622"><label>5</label>Section of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, 56121 Pisa, Italy; <email>sara.galimberti@med.unipi.it</email></aff><author-notes><corresp id="c1-ijms-21-03622"><label>*</label>Correspondence: <email>cesarina.giallongo@unict.it</email> (C.G.); <email>livolti@unict.it</email> (G.L.V.)</corresp><fn id="fn1-ijms-21-03622"><label>&#x02020;</label><p>These authors equally contributed to this work as co-first.</p></fn><fn id="fn2-ijms-21-03622"><label>&#x02021;</label><p>These authors equally contributed to this work as co-last.</p></fn></author-notes><pub-date pub-type="epub"><day>20</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2020</year></pub-date><volume>21</volume><issue>10</issue><elocation-id>3622</elocation-id><history><date date-type="received"><day>29</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>18</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The COVID-19 global pandemic is caused by SARS-CoV-2, and represents an urgent medical and social issue. Unfortunately, there is still not a single proven effective drug available, and therefore, current therapeutic guidelines recommend supportive care including oxygen administration and treatment with antibiotics. Recently, patients have been also treated with off-label therapies which comprise antiretrovirals, anti-inflammatory compounds, antiparasitic agents and plasma from convalescent patients, all with controversial results. The ubiquitin&#x02013;proteasome system (UPS) is important for the maintenance of cellular homeostasis, and plays a pivotal role in viral replication processes. In this review, we discuss several aspects of the UPS and the effects of its inhibition with particular regard to the life cycle of the coronaviruses (CoVs). In fact, proteasome inhibition by various chemical compounds, such as MG132, epoxomycin and bortezomib, may reduce the virus entry into the eucariotic cell, the synthesis of RNA, and the subsequent protein expression necessary for CoVs. Importantly, since UPS inhibitors reduce the cytokine storm associated with various inflammatory conditions, it is reasonable to assume that they might be repurposed for SARS-CoV-2, thus providing an additional tool to counteract both virus replication as well as its most deleterious consequences triggered by abnormal immunological response.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>proteasome inhibitors</kwd><kwd>endoplasmic stress</kwd><kwd>UPR response</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-21-03622"><title>1. Introduction</title><p>Since December 2019, infection with the severe acute respiratory coronavirus 2 (SARS-CoV-2) has become a worldwide emergency (pandemic) for which a rapid action is required [<xref rid="B1-ijms-21-03622" ref-type="bibr">1</xref>,<xref rid="B2-ijms-21-03622" ref-type="bibr">2</xref>]. In particular, COVID-19 (the illness caused by SARS-CoV-2) is overwhelming even well-organized national health care systems on a global scale [<xref rid="B3-ijms-21-03622" ref-type="bibr">3</xref>,<xref rid="B4-ijms-21-03622" ref-type="bibr">4</xref>]. Unfortunately, the symptoms of SARS-CoV-2 infection can vary in an unpredictable manner; there are asymptomatic cases as well as patients suffering from pneumonia, acute respiratory distress syndrome and multisystem organ failure [<xref rid="B5-ijms-21-03622" ref-type="bibr">5</xref>,<xref rid="B6-ijms-21-03622" ref-type="bibr">6</xref>]. Older patients and patients with preexisting respiratory or cardiovascular conditions appear to be at the greatest risk for severe complications and death [<xref rid="B6-ijms-21-03622" ref-type="bibr">6</xref>,<xref rid="B7-ijms-21-03622" ref-type="bibr">7</xref>]. In the absence of a proven effective therapy, current management consists of supportive care, including ventilation and treatment with antibiotics [<xref rid="B8-ijms-21-03622" ref-type="bibr">8</xref>,<xref rid="B9-ijms-21-03622" ref-type="bibr">9</xref>]. Moreover, patients are often treated with off-label therapies, including antiretrovirals, anti-inflammatory compounds, antiparasitic agents, and in a few cases, plasma from recently cured patients [<xref rid="B10-ijms-21-03622" ref-type="bibr">10</xref>,<xref rid="B11-ijms-21-03622" ref-type="bibr">11</xref>,<xref rid="B12-ijms-21-03622" ref-type="bibr">12</xref>,<xref rid="B13-ijms-21-03622" ref-type="bibr">13</xref>]. Antimalarial agents like chloroquine are used to block the virus entry, while new drugs like tocilizumab, anakinra or ruxolitinib [<xref rid="B14-ijms-21-03622" ref-type="bibr">14</xref>], directed against a specific key element of the inflammatory response, are used to switch off the cytokine storm [<xref rid="B15-ijms-21-03622" ref-type="bibr">15</xref>], as are antiviral drugs [<xref rid="B16-ijms-21-03622" ref-type="bibr">16</xref>]. Nevertheless, in the absence of long-term and controlled clinical trials, there is no consensus on a &#x0201c;state of the art&#x0201d; therapeutic approach. Indeed, the use of drugs to stall the virus attack, followed by blocking viral replication and, in patients with signs of higher cytokine/chemokine release, the &#x0201c;pre-emptive&#x0201d; use of anti-IL6 or anti-IL1 blocking antibodies could be proposed [<xref rid="B17-ijms-21-03622" ref-type="bibr">17</xref>,<xref rid="B18-ijms-21-03622" ref-type="bibr">18</xref>]. Here, we review the potential role of proteasome inhibitors, based on previous studies showing that the ubiquitin&#x02013;proteasome system is involved in the replication of a broad range of viruses.</p><sec><title>SARS-CoV-2</title><p>Coronaviruses belong to the Coronaviridae family in the order of Nidovales. They are approximately 65&#x02013;125 nm in diameter and are single-stranded RNA viruses (+ ssRNA). The Coronavirus family includes four subgroups: &#x003b1;-, &#x003b2;-, &#x003b3;- and &#x003b4;-; among them, &#x003b1;- and &#x003b2;-CoV are capable of infecting mammals (<xref ref-type="fig" rid="ijms-21-03622-f001">Figure 1</xref>), while &#x003b3;- and &#x003b4;-CoVs mainly infect birds. Two well-known &#x003b2;-CoVs are SARS-CoV, responsible for the 2003 epidemic started in China (that caused 8000 infections and 800 deaths i.e., a 10% mortality rate), and MERS&#x02013;CoV, which was responsible for the 2012 epidemic that began in Saudi Arabia (causing 2400 infections and 800 deaths i.e., a 35% mortality rate) [<xref rid="B19-ijms-21-03622" ref-type="bibr">19</xref>,<xref rid="B20-ijms-21-03622" ref-type="bibr">20</xref>]. Genomic analysis revealed that the new Coronavirus, SARS-CoV-2 is a &#x003b2;-Coronavirus. The SARS-Cov-2 viral genome is complex and resembles that of other coronaviruses. In particular, 75% of the genome is related to viral replicase genes from two open reading frames (ORFs), i.e., ORF1a and ORF1b, encoding for two polyproteins, pp1a (486 kDa) and pp1ab (790 kDa).The 1 ribo-some frame-shift occurs immediately upstream of the ORF1a stop codon, which allows the continuous translation of ORF1b to occur, producing a large polypeptide (pp1ab, 740&#x02013;810 kDa) which is divided into 15 nsps. Proteolytic cleavage is mediated by the viral proteases nsp3 and nsp5 which, respectively, host a papain-like placenta domain and a 3C-like protease domain. Moreover, at short motifs called transcription-regulatory sequences (TRSs) that are located immediately adjacent to ORFs, the protease domain contains a conserved 6&#x02013;7 nt core sequence (CS) surrounded by variable sequences [<xref rid="B21-ijms-21-03622" ref-type="bibr">21</xref>]. Coronaviruses exhibit a round morphology and are constituted of several components, such as glycoprotein S (Spike), organized in trimers on the external part of the virion resembling a crown, from which they take their name; this protein determines the virus specificity for epithelial cells. In fact, it has been suggested that SARS-CoV-2 enters the host cell through the angiotensin-2 conversion receptor, ACE2, and CD26 (like SARS-CoV), expressed at both pulmonary and gastrointestinal levels (that&#x02019;s why there are also symptoms at these compartments) [<xref rid="B22-ijms-21-03622" ref-type="bibr">22</xref>]. Protein M crosses the envelope and interacts within the virion with the RNA protein complex. HE protein, the hemagglutinin esterase, is important during the virus release phase inside the host cell. The Protein E helps protein S attach to the target cells membranes. Finally, RNA gives rise to 7 viral proteins and is associated with the N protein, which increases its stability (<xref ref-type="fig" rid="ijms-21-03622-f001">Figure 1</xref>).</p><p>According to the evolutionary tree, SARS-CoV-2 is located close to the SARS-coronavirus group [<xref rid="B23-ijms-21-03622" ref-type="bibr">23</xref>,<xref rid="B24-ijms-21-03622" ref-type="bibr">24</xref>]. Recent studies have indicated significant variations in SARS-CoV and SARS-CoV-2, such as the absence of protein 8a and the fluctuation in the number of amino acids in protein 8b and 3c in SARS-CoV-2 [<xref rid="B6-ijms-21-03622" ref-type="bibr">6</xref>]. Spike glycoprotein from the Wuhan coronavirus was modified by homologous recombination. Particularly, the spike glycoprotein of SARS-CoV-2 is a mixture of SARS-CoV bat and an unknown Beta-CoV [<xref rid="B24-ijms-21-03622" ref-type="bibr">24</xref>]. The SARS-CoV-2 genome is 29.9 kb [<xref rid="B25-ijms-21-03622" ref-type="bibr">25</xref>], while those of SARS-CoV and MERS-CoV are 27.9 and 30.1 kb, respectively [<xref rid="B26-ijms-21-03622" ref-type="bibr">26</xref>]. The glycoprotein S comprises two subunits, S1 and S2 [<xref rid="B27-ijms-21-03622" ref-type="bibr">27</xref>]. S1 determines the viral host flow rate and cell tropism with the key function domain&#x02013;receptor-binding domain (RBD), while S2 mediates cell&#x02013;cell membrane fusion through heptad repeat 1 (HR1) and 2 (HR2) [<xref rid="B28-ijms-21-03622" ref-type="bibr">28</xref>,<xref rid="B29-ijms-21-03622" ref-type="bibr">29</xref>]. Starting from the viral RNA, the synthesis of two 1a/1ab polyproteins (pp1a pp1ab) takes place in the host [<xref rid="B30-ijms-21-03622" ref-type="bibr">30</xref>]. Transcription works through the replication&#x02013;transcription complex (RTC), organized in double membrane vesicles, which continuously replicates and synthesizes subgenomic RNAs [<xref rid="B31-ijms-21-03622" ref-type="bibr">31</xref>] and, in turn, encodes accessory and structural proteins. The endoplasmic reticulum (ER) and Golgi [<xref rid="B32-ijms-21-03622" ref-type="bibr">32</xref>], genomic RNA, N protein and envelope glycoproteins come together to form viral bud particles. The vesicles containing virions then merge with the plasma membrane and release the virus. Transcription termination occurs in regulatory transcription sequences, located between open reading frames (ORFs), i.e., models for the production of subgenomic mRNA. In CoV, there are about 6 ORFs, and a frame-shift between ORF1a and ORF1b drives the production of pp1a and pp1ab, while the other ORFs encode for structural proteins S, E, M, N [<xref rid="B30-ijms-21-03622" ref-type="bibr">30</xref>] and accessory proteins that interfere with the host&#x02019;s innate immune response [<xref rid="B2-ijms-21-03622" ref-type="bibr">2</xref>]. As mentioned, it has been suggested that SARS-CoV-2, like SARS-CoV, uses the ACE2 receptor to enter the host cell [<xref rid="B33-ijms-21-03622" ref-type="bibr">33</xref>], but a N501T mutation in protein S of SARS-CoV-2 may result in a better binding affinity for ACE2 [<xref rid="B34-ijms-21-03622" ref-type="bibr">34</xref>]. Systematic detection of &#x003b2;-CoV receptors has shown that human cells expressing ACE2 have improved SARS-CoV-2 access [<xref rid="B35-ijms-21-03622" ref-type="bibr">35</xref>].</p><p>Angeletti et al. compared the gene sequence of SARSars-Cov-2 with that of SARSars-CoV. They analyzed the transmembrane helical segments in coded ORF1ab 2 (nsp2) and nsp3 and found that position 723 has a residue of serine instead of glycine, while position 1010 is occupied by proline instead of isoleucine [<xref rid="B36-ijms-21-03622" ref-type="bibr">36</xref>]. The issue of viral mutations is the key to explaining potential relapses of the disease. At the protein level, no amino acid substitutions occur in rotavirus nonstructural protein families (NSPs), NSP7, NSP13, envelope, matrix or accessory proteins p6 and 8b, with the exception of NSP2, NSP3, spike protein, subdomain below, or RBD. Other recent research [<xref rid="B37-ijms-21-03622" ref-type="bibr">37</xref>] has suggested that the mutation in NSP2 and NSP3 has a role in the infectious ability and differentiation mechanism of SARS-CoV-2.</p></sec></sec><sec id="sec2-ijms-21-03622"><title>2. Currently-Available Therapies</title><p>To date, there is no vaccine available, nor a specific antiviral therapy for SARS-CoV-2. The current therapeutic strategies used to cope with this pandemic are mainly based on symptomatic and respiratory support. On 28 January 2020, the WHO published a document summarizing its guidelines and scientific evidence derived from the treatment of previous HCoV epidemics [<xref rid="B30-ijms-21-03622" ref-type="bibr">30</xref>]. Furthermore, the scientific world works constantly and is looking for an effective therapy, mainly based on strategies previously used against SARS-CoV and MERS - CoV. Interferons nebulization and various antivirals were initially used, including Nafamostat, Nnitazoxanide, Rribavirin, Penciclovir, Ffavipiravine, Rritonavir, Baricitinib, Lopinavir, Oseltamir and Arbidol. However, Remdesivir has been shown to be most effective in reducing viral load [<xref rid="B38-ijms-21-03622" ref-type="bibr">38</xref>] (GS5734). As an RNA polymerase inhibitor, it has been shown, alone or in combination with chloroquine or interferon-&#x003b2;, to effectively block the replication of SARS-CoV-2 [<xref rid="B39-ijms-21-03622" ref-type="bibr">39</xref>,<xref rid="B40-ijms-21-03622" ref-type="bibr">40</xref>,<xref rid="B41-ijms-21-03622" ref-type="bibr">41</xref>]. Based on experience in the fight against SARS-CoV and MERS-CoV, antiviral drugs and systemic treatment with corticosteroids commonly used previously in clinical practice, including neuraminidase inhibitors (Oseltamivir, Peramivir, Zanamivir, etc.), Ganciclovir, Aciclovir and Rribavirin, as well as methylprednisolone [<xref rid="B42-ijms-21-03622" ref-type="bibr">42</xref>,<xref rid="B43-ijms-21-03622" ref-type="bibr">43</xref>] for the influenza virus, are not valid for COVID-19 and are not recommended. Another effective drug is chloroquine (500 mg every 12 h) and hydroxychloroquine (200 mg every 12 h), drugs used for many years in the treatment of malaria, and today also in the treatment of rheumatoid arthritis. Several possible mechanisms have been studied. Chloroquine can inhibit the pH-dependent phases of the replication of different viruses [<xref rid="B44-ijms-21-03622" ref-type="bibr">44</xref>], with a powerful effect on the infection and spread of SARS-CoV [<xref rid="B45-ijms-21-03622" ref-type="bibr">45</xref>]. Furthermore, chloroquine has immuno-modulatory effects, suppressing the production/release of TNF-&#x003b1; and IL-6. Several studies have found that chloroquine interferes with the glycosylation of SARS-CoV cell receptors [<xref rid="B45-ijms-21-03622" ref-type="bibr">45</xref>], and has worked in both the entry and postentry stages of COVID-19 infection in Vero E6 cells [<xref rid="B41-ijms-21-03622" ref-type="bibr">41</xref>]. In Italy, a large survey conducted by the National Cancer Institute and the Pascale Foundation of Naples focused on the use of tolicizumab. It is a humanized IgG1 monoclonal antibody, directed against the IL-6 receptor and commonly used in the treatment of rheumatoid arthritis. Passive immunization has been successfully used for the treatment of infectious diseases, and 80 SARS patients were treated with convalescent plasma during the last major outbreak, while the same treatment did not occur for MERS. Since many patients have recovered despite the high number of deaths, this could also be a strategy for SARS-CoV-2.</p></sec><sec id="sec3-ijms-21-03622"><title>3. Inhibition of the Ubiquitin&#x02013;Proteasome System</title><p>The ubiquitin&#x02013;proteasome system (UPS) is important for the maintenance of cellular homeostasis and also in viral replication processes. The UPS system is a complex process that leads to the degradation of ubiquitinated target proteins through the cutting action of the proteosome. Proteosome inhibitors are therefore molecules that are capable of inhibiting proteoasome activity, inducing the inhibition of the UPS response. We, in this review, focus our attention on the inhibition of proteasome activity by drugs already routinely used in many tumor pathologies. Some studies have focused on the role played by the ubiquitin&#x02013;proteasome system and its inhibition in the process of entry and replication of the coronavirus [<xref rid="B46-ijms-21-03622" ref-type="bibr">46</xref>]. Moreover, in the destabilization of antiviral proteins, viruses retain proviral or viral proteins by manipulating the ubiquitination processes through the expression of their own deubiquitination proteins (DUBs) [<xref rid="B47-ijms-21-03622" ref-type="bibr">47</xref>], which have also been described for SARS-CoV [<xref rid="B48-ijms-21-03622" ref-type="bibr">48</xref>,<xref rid="B49-ijms-21-03622" ref-type="bibr">49</xref>]. On the other hand, the replication of numerous viruses also depends heavily on the activity of a functional UPS. Several studies have shown that virus infection leads to the accumulation of protein&#x02013;ubiquitin conjugates, suggesting an important role of the increased ubiquitination process in ubiquitin&#x02013;proteasome-mediated viral replication or protein degradation. Furthermore, the accumulation of proteins explained by the inhibition of proteasome activity causes a blockage of protein synthesis, endoplasmatic reticulum stress and cell death, leading to the inhibition of viral replication [<xref rid="B50-ijms-21-03622" ref-type="bibr">50</xref>,<xref rid="B51-ijms-21-03622" ref-type="bibr">51</xref>].</p><p>The best-known proteasome inhibitor is Bortezomib (Valcade) [<xref rid="B50-ijms-21-03622" ref-type="bibr">50</xref>], which was approved in 2008 as a first-line drug in the treatment of multiple myeloma. Other inhibitors are MG132, Lactacistin, Carfilzomib, Ixazomib and others which are able to target the 20S and 19S subunits (<xref ref-type="fig" rid="ijms-21-03622-f002">Figure 2</xref>) [<xref rid="B49-ijms-21-03622" ref-type="bibr">49</xref>,<xref rid="B52-ijms-21-03622" ref-type="bibr">52</xref>]. Interestingly, Computational Drug Repurposing Studies showed that Carfilzomib is a good candidate for the treatment of COVID-19 [<xref rid="B53-ijms-21-03622" ref-type="bibr">53</xref>].</p><p>As mentioned, one of the effects of coronavirus infection is the pro-inflammatory cytokine storm that occurs mainly in patients with severe respiratory conditions. The inhibition of the ubiquitin&#x02013;proteasome system has proven effective in reducing the inflammatory response. In particular, a study by Moutzouris et al. [<xref rid="B54-ijms-21-03622" ref-type="bibr">54</xref>] evaluated the anti-inflammatory effect of UPS inhibition in an airway smooth muscle (ASM) cell line. Specifically, this study demonstrated that cells treated with the MG132 inhibitor showed a reduction in IL-6 levels and other cytokines like sICAM-1, IP-10, MCP-1, MIF, RANTES, but also in the upregulation of MKP-1, a negative regulator of the serine/threonine protein kinases MAPK, which, once activated, plays a crucial role in a wide variety of cellular functions, ranging from proliferation to migration and synthesis of fibrotic and inflammatory proteins, including cytokines. Therefore, MAPK inhibition has emerged as an attractive strategy for reversing inflammation and remodeling in a wide variety of chronic inflammatory conditions [<xref rid="B54-ijms-21-03622" ref-type="bibr">54</xref>]. Therefore, overall, the Moutzouris study suggests that UPS inhibition is an effective means of increasing the levels of the MAPK deactivator, MKP-1, and that, therefore, it could represent a possible therapeutic target in inflammatory conditions. Despite this, it is known that the ubiquitin&#x02013;proteasome system is also important for the endocytosis and maturation of some viruses. Already in 2005, after the first SARS-CoV epidemic, in a study by Yi Yu et al. concerning the murine hepatitis virus (MHV-JHM strain, belonging to the Coronaviridae family), it was shown that the ubiquitin&#x02013;proteasome system is involved in the release of the virus from the endosome to the cytosol during the virus entry phase. Proteasome inhibitors (lactacistin and MG132) inhibit MHV replication, demonstrating that the ubiquitin&#x02013;proteasome system is involved in the early stages of virus replication, as the inhibitory effect was observed mainly from 0 to 6 h after treatment. It was stressed, however, that proteasome inhibition does not block the internalization of the virus. Furthermore, in the presence of MG132, most viruses remained in the vesicles, both endosomes and lysosomes, and therefore, are protected by RNase digestion [<xref rid="B55-ijms-21-03622" ref-type="bibr">55</xref>]. Therefore, although MHV can be internalized in the cell in the absence of a functional ubiquitin&#x02013;proteasome system, viruses within endosomes or lysosomes cannot be released into the cytosol [<xref rid="B55-ijms-21-03622" ref-type="bibr">55</xref>]. Indeed, SARS-CoV, which binds to its functional receptor ACE2 [<xref rid="B56-ijms-21-03622" ref-type="bibr">56</xref>], is internalized by endocytosis, and viral RNA is released from the endosome [<xref rid="B56-ijms-21-03622" ref-type="bibr">56</xref>,<xref rid="B57-ijms-21-03622" ref-type="bibr">57</xref>,<xref rid="B58-ijms-21-03622" ref-type="bibr">58</xref>,<xref rid="B59-ijms-21-03622" ref-type="bibr">59</xref>]. In the cytosol, the SARS-CoV genome is translated into two large polyproteins which are processed autocatalytically to produce nonstructural proteins (nsps), including all the nsps of the replicase viral complex [<xref rid="B60-ijms-21-03622" ref-type="bibr">60</xref>,<xref rid="B61-ijms-21-03622" ref-type="bibr">61</xref>,<xref rid="B62-ijms-21-03622" ref-type="bibr">62</xref>]. Protected by double membrane vesicles (DMV), most likely originating from endoplasmic reticulum (ER) membranes [<xref rid="B63-ijms-21-03622" ref-type="bibr">63</xref>], the genome is replicated and, by generating specific sets of subgenomic mRNA, structural and specific accessory SARS-CoV proteins are produced [<xref rid="B61-ijms-21-03622" ref-type="bibr">61</xref>,<xref rid="B62-ijms-21-03622" ref-type="bibr">62</xref>]. After assembly and budding processes in the endoplasmic reticulum of the Golgi intermediate compartment (ERGIC) [<xref rid="B64-ijms-21-03622" ref-type="bibr">64</xref>,<xref rid="B65-ijms-21-03622" ref-type="bibr">65</xref>], mature virions are released by exocytosis. Proteasome inhibition by various chemical compounds (e.g., MG132, Eepoxomycin and VelcadeBortezomib) seems not only to compromise the entry, but also the synthesis of RNA and the subsequent protein expression of different CoVs (e.g., Hepatitis Virus of mouse [MHV], feline infectious peritonitis virus, and severe acute respiratory syndrome CoV) [<xref rid="B66-ijms-21-03622" ref-type="bibr">66</xref>]. A 2010 study by Raaben et al. showed that in cells treated with UPS chemical inhibitors, the synthesis of the viral CoV RNA and the subsequent protein expression were strongly reduced in all experimental conditions, while the entry of the virus was influenced only by chemical proteasome inhibitors [<xref rid="B66-ijms-21-03622" ref-type="bibr">66</xref>]. In particular, the authors attempted to determine whether the inhibition of virus infection caused by MG132 was specific to this proteasome inhibitor or whether it was also observed when other proteasome inhibitors were used. Although MG132 has been shown to also inhibit proteases other than proteasome (i.e., cathepsin A and tripeptidyl peptidase II) [<xref rid="B67-ijms-21-03622" ref-type="bibr">67</xref>], Eepoxomomine, Llactacystine and Velcade Bortezomib affect the proteasome more specifically [<xref rid="B68-ijms-21-03622" ref-type="bibr">68</xref>,<xref rid="B69-ijms-21-03622" ref-type="bibr">69</xref>,<xref rid="B70-ijms-21-03622" ref-type="bibr">70</xref>]. Finally, a 2012 study showed conflicting data with previous work. Schneider et al. showed that the proteasomal inhibitor MG132 strongly inhibits the replication of SARS-CoV by interfering with the early stages of the viral life cycle, but other inhibitors (e.g., Lactacistin and Bbortezomib) only marginally affected viral replication, suggesting that the effect of MG132 is independent of proteasome inhibition, since MG132 also inhibits m&#x02013;calpain. Interestingly, these authors observed that by using a calpain inhibitor (MDL28170), virus replication was inhibited, suggesting that MG132 does not inhibit SARS-CoV replication by ER stress induction, unexplained protein response or autophagy [<xref rid="B47-ijms-21-03622" ref-type="bibr">47</xref>]. Since few studies to date have demonstrated the effects on coronavirus replication, we hypothesize that proteasomal inhibitors may negatively modulate virus replication, primarily acting on blocking protein synthesis due to an increase in stress on the plasma reticulum, and therefore, on the activation of the UPS. In the few papers published, bortezomib did not show great efficacy, but we have new inhibitors, some of which have the ability to bind the proteasome in an irreversible way, such as Ccarfilzomib. Interestingly, Wang et al. performed a molecular dynamics simulation followed by binding free energy calculations, demonstrating that Carfilzomib presented the best binding free energy, and therefore supporting the possible use of this proteasome inhibitor against COVID-19 [<xref rid="B53-ijms-21-03622" ref-type="bibr">53</xref>].</p></sec><sec sec-type="conclusions" id="sec4-ijms-21-03622"><title>4. Conclusions</title><p>In the absence of definitive protocols, effective antiviral care and a vaccine against SARS-CoV-2, the scientific community should explore possible therapeutic strategies, relying mainly on those used in previous epidemics. In this review, we summarized the current knowledge regarding the use of drugs, and in particular of ubiquitin&#x02013;proteasome system inhibitors, which were proven to be powerful tools in reducing the cytokine storm and in inhibiting virus replication for other coronaviruses (<xref ref-type="fig" rid="ijms-21-03622-f003">Figure 3</xref>). Several molecules appear to be promising candidates; in particular, MG132, epoxomycin, bortezomib and carfilzomib have the potential to affect both viral replication as well as pneumonia and acute respiratory distress syndrome. Further studies are now warranted in order to establish the clinical efficacy of these compounds and to compare the clinical outcomes of patients.</p></sec></body><back><notes><title>Author Contributions</title><p>Conceptualization, D.T., L.L., A.L., G.L., N.T., C.G., S.G. and G.L.V.; validation, N.T., G.A.P., D.T., L.L.; writing&#x02014;original draft preparation, D.T., C.G., G.A.P., G.L.V., A.L., N.T.; supervision, A.L., S.G., G.A.P. and G.L.V.; writing&#x02014;review and editing, S.G., D.T., A.L., G.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-21-03622"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Horby</surname><given-names>P.W.</given-names></name><name><surname>Hayden</surname><given-names>F.G.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>A novel coronavirus outbreak of global health concern</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30185-9</pub-id><pub-id pub-id-type="pmid">31986257</pub-id></element-citation></ref><ref id="B2-ijms-21-03622"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y.R.</given-names></name><name><surname>Cao</surname><given-names>Q.D.</given-names></name><name><surname>Hong</surname><given-names>Z.S.</given-names></name><name><surname>Tan</surname><given-names>Y.Y.</given-names></name><name><surname>Chen</surname><given-names>S.D.</given-names></name><name><surname>Jin</surname><given-names>H.J.</given-names></name><name><surname>Tan</surname><given-names>K.S.</given-names></name><name><surname>Wang</surname><given-names>D.Y.</given-names></name><name><surname>Yan</surname><given-names>Y.</given-names></name></person-group><article-title>The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak&#x02014;An update on the status</article-title><source>Mil. Med. Res.</source><year>2020</year><volume>7</volume><fpage>10</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/s40779-020-00240-0</pub-id><?supplied-pmid 32169119?><pub-id pub-id-type="pmid">32151283</pub-id></element-citation></ref><ref id="B3-ijms-21-03622"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riou</surname><given-names>J.</given-names></name><name><surname>Althaus</surname><given-names>C.L.</given-names></name></person-group><article-title>Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020</article-title><source>Eurosurveillance</source><year>2020</year><volume>25</volume><elocation-id>2000058</elocation-id><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.4.2000058</pub-id><?supplied-pmid 32019669?><pub-id pub-id-type="pmid">32019669</pub-id></element-citation></ref><ref id="B4-ijms-21-03622"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Gayle</surname><given-names>A.A.</given-names></name><name><surname>Wilder-Smith</surname><given-names>A.</given-names></name><name><surname>Rockl&#x000f6;v</surname><given-names>J.</given-names></name></person-group><article-title>The reproductive number of COVID-19 is higher compared to SARS coronavirus</article-title><source>J. Travel Med.</source><year>2020</year><volume>27</volume><pub-id pub-id-type="doi">10.1093/jtm/taaa021</pub-id><?supplied-pmid 32052846?><pub-id pub-id-type="pmid">32052846</pub-id></element-citation></ref><ref id="B5-ijms-21-03622"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.W.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Kok</surname><given-names>K.H.</given-names></name><name><surname>To</surname><given-names>K.K.W.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Xing</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Yip</surname><given-names>C.C.Y.</given-names></name><name><surname>Poon</surname><given-names>R.W.S.</given-names></name><etal/></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster</article-title><source>Lancet</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30154-9</pub-id></element-citation></ref><ref id="B6-ijms-21-03622"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>A.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Meng</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China</article-title><source>Cell Host Microbe</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.chom.2020.02.001</pub-id></element-citation></ref><ref id="B7-ijms-21-03622"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Niu</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Zhu</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding</article-title><source>Lancet</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id></element-citation></ref><ref id="B8-ijms-21-03622"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shereen</surname><given-names>M.A.</given-names></name><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Kazmi</surname><given-names>A.</given-names></name><name><surname>Bashir</surname><given-names>N.</given-names></name><name><surname>Siddique</surname><given-names>R.</given-names></name></person-group><article-title>COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses</article-title><source>J. Adv. Res.</source><year>2020</year><volume>24</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.jare.2020.03.005</pub-id><pub-id pub-id-type="pmid">32257431</pub-id></element-citation></ref><ref id="B9-ijms-21-03622"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>L.T.</given-names></name><name><surname>Nguyen</surname><given-names>T.V.</given-names></name><name><surname>Luong</surname><given-names>Q.C.</given-names></name><name><surname>Nguyen</surname><given-names>T.V.</given-names></name><name><surname>Nguyen</surname><given-names>H.T.</given-names></name><name><surname>Le</surname><given-names>H.Q.</given-names></name><name><surname>Nguyen</surname><given-names>T.T.</given-names></name><name><surname>Cao</surname><given-names>T.M.</given-names></name><name><surname>Pham</surname><given-names>Q.D.</given-names></name></person-group><article-title>Importation and human-to-human transmission of a novel coronavirus in Vietnam</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>872</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1056/NEJMc2001272</pub-id><pub-id pub-id-type="pmid">31991079</pub-id></element-citation></ref><ref id="B10-ijms-21-03622"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parry</surname><given-names>J.</given-names></name></person-group><article-title>China coronavirus: Cases surge as official admits human to human transmission</article-title><source>BMJ</source><year>2020</year><pub-id pub-id-type="doi">10.1136/bmj.m236</pub-id></element-citation></ref><ref id="B11-ijms-21-03622"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id></element-citation></ref><ref id="B12-ijms-21-03622"><label>12.</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez-S&#x000e1;nchez</surname><given-names>G.</given-names></name></person-group><article-title>Potential use of ozone in SARS-CoV-2/COVID-19</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.google.com.hk/url?sa=t&#x00026;rct=j&#x00026;q=&#x00026;esrc=s&#x00026;source=web&#x00026;cd=1&#x00026;ved=2ahUKEwjlkamFncLpAhWwGqYKHZ1YDwsQFjAAegQIAhAB&#x00026;url=https%3A%2F%2Faepromo.org%2Fcoronavirus%2Fpdfs_doc_ISCO3%2FCovid19_en.pdf&#x00026;usg=AOvVaw2wQjtRjoH-KWfgGcsosl22">https://www.google.com.hk/url?sa=t&#x00026;rct=j&#x00026;q=&#x00026;esrc=s&#x00026;source=web&#x00026;cd=1&#x00026;ved=2ahUKEwjlkamFncLpAhWwGqYKHZ1YDwsQFjAAegQIAhAB&#x00026;url=https%3A%2F%2Faepromo.org%2Fcoronavirus%2Fpdfs_doc_ISCO3%2FCovid19_en.pdf&#x00026;usg=AOvVaw2wQjtRjoH-KWfgGcsosl22</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-19">(accessed on 19 May 2020)</date-in-citation></element-citation></ref><ref id="B13-ijms-21-03622"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauro</surname><given-names>R.D.</given-names></name><name><surname>Cantarella</surname><given-names>G.</given-names></name><name><surname>Bernardini</surname><given-names>R.</given-names></name><name><surname>Rosa</surname><given-names>M.D.</given-names></name><name><surname>Barbagallo</surname><given-names>I.</given-names></name><name><surname>Distefano</surname><given-names>A.</given-names></name><name><surname>Longhitano</surname><given-names>L.</given-names></name><name><surname>Vicario</surname><given-names>N.</given-names></name><name><surname>Nicolosi</surname><given-names>D.</given-names></name><name><surname>Lazzarino</surname><given-names>G.</given-names></name><etal/></person-group><article-title>The biochemical and pharmacological properties of ozone: The smell of protection in acute and chronic diseases</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>634</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20030634</pub-id><?supplied-pmid 30717203?><pub-id pub-id-type="pmid">30717203</pub-id></element-citation></ref><ref id="B14-ijms-21-03622"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elli</surname><given-names>E.M.</given-names></name><name><surname>Barat&#x000e8;</surname><given-names>C.</given-names></name><name><surname>Mendicino</surname><given-names>F.</given-names></name><name><surname>Palandri</surname><given-names>F.</given-names></name><name><surname>Palumbo</surname><given-names>G.A.</given-names></name></person-group><article-title>Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib</article-title><source>Front. Oncol.</source><year>2019</year><volume>9</volume><fpage>1186</fpage><pub-id pub-id-type="doi">10.3389/fonc.2019.01186</pub-id><?supplied-pmid 31788449?><pub-id pub-id-type="pmid">31788449</pub-id></element-citation></ref><ref id="B15-ijms-21-03622"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Qin</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>X.</given-names></name><etal/></person-group><article-title>The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China</article-title><source>Clin. Immunol.</source><year>2020</year><volume>214</volume><fpage>108393</fpage><pub-id pub-id-type="doi">10.1016/j.clim.2020.108393</pub-id><?supplied-pmid 32222466?><pub-id pub-id-type="pmid">32222466</pub-id></element-citation></ref><ref id="B16-ijms-21-03622"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosa</surname><given-names>S.G.V.</given-names></name><name><surname>Santos</surname><given-names>W.C.</given-names></name></person-group><article-title>Clinical trials on drug repositioning for COVID-19 treatment</article-title><source>Revista Panamericana de Salud P&#x000fa;blica</source><year>2020</year><pub-id pub-id-type="doi">10.26633/RPSP.2020.40</pub-id></element-citation></ref><ref id="B17-ijms-21-03622"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>P.</given-names></name><name><surname>Ronconi</surname><given-names>G.</given-names></name><name><surname>Caraffa</surname><given-names>A.</given-names></name><name><surname>Gallenga</surname><given-names>C.E.</given-names></name><name><surname>Ross</surname><given-names>R.</given-names></name><name><surname>Frydas</surname><given-names>I.</given-names></name><name><surname>Kritas</surname><given-names>S.K.</given-names></name></person-group><article-title>Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: Anti-inflammatory strategies</article-title><source>J. Biol. Regul. Homeost. Agents</source><year>2020</year><pub-id pub-id-type="doi">10.23812/CONTI-E</pub-id></element-citation></ref><ref id="B18-ijms-21-03622"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galimberti</surname><given-names>S.</given-names></name><name><surname>Baldini</surname><given-names>C.</given-names></name><name><surname>Barate</surname><given-names>C.</given-names></name><name><surname>Ricci</surname><given-names>F.</given-names></name><name><surname>Balducci</surname><given-names>S.</given-names></name><name><surname>Grassi</surname><given-names>S.</given-names></name><name><surname>Ferro</surname><given-names>F.</given-names></name><name><surname>Buda</surname><given-names>G.</given-names></name><name><surname>Benedetti</surname><given-names>E.</given-names></name><name><surname>Fazzi</surname><given-names>R.</given-names></name><etal/></person-group><article-title>The CoV-2 outbreak: How hematologists could help to fight Covid-19</article-title><source>Pharmacol. Res.</source><year>2020</year><volume>157</volume><fpage>104866</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104866</pub-id><pub-id pub-id-type="pmid">32387301</pub-id></element-citation></ref><ref id="B19-ijms-21-03622"><label>19.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Summary of Probable SARS Cases with Onset of Illness from 1 November 2002 to 31 July 2003</article-title><year>2004</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/country/table2004_04_21/en/">https://www.who.int/csr/sars/country/table2004_04_21/en/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-05-19">(accessed on 19 May 2020)</date-in-citation></element-citation></ref><ref id="B20-ijms-21-03622"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Van Kerkhove</surname><given-names>M.D.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name></person-group><article-title>Middle East respiratory syndrome</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1063</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)33221-0</pub-id><pub-id pub-id-type="pmid">32145185</pub-id></element-citation></ref><ref id="B21-ijms-21-03622"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>J.Y.</given-names></name><name><surname>Yang</surname><given-names>J.S.</given-names></name><name><surname>Kim</surname><given-names>J.W.</given-names></name><name><surname>Kim</surname><given-names>V.N.</given-names></name><name><surname>Chang</surname><given-names>H.</given-names></name></person-group><article-title>The Architecture of SARS-CoV-2 Transcriptome</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cell.2020.04.011</pub-id></element-citation></ref><ref id="B22-ijms-21-03622"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name></person-group><article-title>Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2</article-title><source>Science</source><year>2020</year><pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id></element-citation></ref><ref id="B23-ijms-21-03622"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Azhar</surname><given-names>E.I.</given-names></name><name><surname>Madani</surname><given-names>T.A.</given-names></name><name><surname>Ntoumi</surname><given-names>F.</given-names></name><name><surname>Kock</surname><given-names>R.</given-names></name><name><surname>Dar</surname><given-names>O.</given-names></name><name><surname>Ippolito</surname><given-names>G.</given-names></name><name><surname>Mchugh</surname><given-names>T.D.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name><name><surname>Drosten</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health &#x02014;The latest 2019 novel coronavirus outbreak in Wuhan, China</article-title><source>Int. J. Infect. Dis.</source><year>2020</year><volume>91</volume><fpage>264</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.01.009</pub-id><?supplied-pmid 31953166?><pub-id pub-id-type="pmid">31953166</pub-id></element-citation></ref><ref id="B24-ijms-21-03622"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Si</surname><given-names>H.-R.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>X.-L.</given-names></name><name><surname>Anderson</surname><given-names>D.E.</given-names></name><name><surname>Shi</surname><given-names>Z.-L.</given-names></name><name><surname>Wang</surname><given-names>L.-F.</given-names></name><name><surname>Zhou</surname><given-names>P.</given-names></name></person-group><article-title>Discovery of Bat Coronaviruses through Surveillance and Probe Capture-Based Next-Generation Sequencing</article-title><source>mSphere</source><year>2020</year><pub-id pub-id-type="doi">10.1128/mSphere.00807-19</pub-id><?supplied-pmid 31996413?><pub-id pub-id-type="pmid">31996413</pub-id></element-citation></ref><ref id="B25-ijms-21-03622"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.M.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>Z.G.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Tao</surname><given-names>Z.W.</given-names></name><name><surname>Tian</surname><given-names>J.H.</given-names></name><name><surname>Pei</surname><given-names>Y.Y.</given-names></name><etal/></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><?supplied-pmid 32015508?><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="B26-ijms-21-03622"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Wit</surname><given-names>E.</given-names></name><name><surname>Van Doremalen</surname><given-names>N.</given-names></name><name><surname>Falzarano</surname><given-names>D.</given-names></name><name><surname>Munster</surname><given-names>V.J.</given-names></name></person-group><article-title>SARS and MERS: Recent insights into emerging coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><year>2016</year><volume>14</volume><fpage>523</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.81</pub-id><pub-id pub-id-type="pmid">27344959</pub-id></element-citation></ref><ref id="B27-ijms-21-03622"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Current advancements and potential strategies in the development of MERS-CoV vaccines</article-title><source>Expert Rev. Vaccines</source><year>2014</year><volume>13</volume><fpage>761</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1586/14760584.2014.912134</pub-id><pub-id pub-id-type="pmid">24766432</pub-id></element-citation></ref><ref id="B28-ijms-21-03622"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Lan</surname><given-names>Q.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Ying</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein</article-title><source>Cell. Mol. Immunol.</source><year>2020</year><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1038/s41423-020-0374-2</pub-id><pub-id pub-id-type="pmid">31611651</pub-id></element-citation></ref><ref id="B29-ijms-21-03622"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Ojcius</surname><given-names>D.M.</given-names></name><name><surname>Pan</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China</article-title><source>Microbes Infect.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.micinf.2020.01.003</pub-id></element-citation></ref><ref id="B30-ijms-21-03622"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cascella</surname><given-names>M.</given-names></name><name><surname>Rajnik</surname><given-names>M.</given-names></name><name><surname>Cuomo</surname><given-names>A.</given-names></name><name><surname>Dulebohn</surname><given-names>S.C.</given-names></name><name><surname>Di Napoli</surname><given-names>R.</given-names></name></person-group><source>Features, Evaluation and Treatment Coronavirus (COVID-19)</source><publisher-name>StatPearls</publisher-name><publisher-loc>Bethesda, MD, USA</publisher-loc><year>2020</year></element-citation></ref><ref id="B31-ijms-21-03622"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>S.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Tien</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Identification of Novel Subgenomic RNAs and Noncanonical Transcription Initiation Signals of Severe Acute Respiratory Syndrome Coronavirus</article-title><source>J. Virol.</source><year>2005</year><pub-id pub-id-type="doi">10.1128/JVI.79.9.5288-5295.2005</pub-id></element-citation></ref><ref id="B32-ijms-21-03622"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrier</surname><given-names>A.</given-names></name><name><surname>Bonnin</surname><given-names>A.</given-names></name><name><surname>Desmarets</surname><given-names>L.</given-names></name><name><surname>Danneels</surname><given-names>A.</given-names></name><name><surname>Goffard</surname><given-names>A.</given-names></name><name><surname>Rouill&#x000e9;</surname><given-names>Y.</given-names></name><name><surname>Dubuisson</surname><given-names>J.</given-names></name><name><surname>Belouzard</surname><given-names>S.</given-names></name></person-group><article-title>The C-terminal domain of the MERS coronavirusMprotein contains a trans-Golgi network localization signal</article-title><source>J. Biol. Chem.</source><year>2019</year><pub-id pub-id-type="doi">10.1074/jbc.RA119.008964</pub-id></element-citation></ref><ref id="B33-ijms-21-03622"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Hao</surname><given-names>P.</given-names></name></person-group><article-title>Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission</article-title><source>Sci. China Life Sci.</source><year>2020</year><volume>63</volume><fpage>457</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1007/s11427-020-1637-5</pub-id><pub-id pub-id-type="pmid">32009228</pub-id></element-citation></ref><ref id="B34-ijms-21-03622"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Shang</surname><given-names>J.</given-names></name><name><surname>Graham</surname><given-names>R.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus</article-title><source>J. Virol.</source><year>2020</year><pub-id pub-id-type="doi">10.1128/JVI.00127-20</pub-id><?supplied-pmid 31996437?><pub-id pub-id-type="pmid">31996437</pub-id></element-citation></ref><ref id="B35-ijms-21-03622"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letko</surname><given-names>M.</given-names></name><name><surname>Marzi</surname><given-names>A.</given-names></name><name><surname>Munster</surname><given-names>V.</given-names></name></person-group><article-title>Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses</article-title><source>Nat. Microbiol.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41564-020-0688-y</pub-id><?supplied-pmid 32094589?><pub-id pub-id-type="pmid">32094589</pub-id></element-citation></ref><ref id="B36-ijms-21-03622"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovanetti</surname><given-names>M.</given-names></name><name><surname>Benvenuto</surname><given-names>D.</given-names></name><name><surname>Angeletti</surname><given-names>S.</given-names></name><name><surname>Ciccozzi</surname><given-names>M.</given-names></name></person-group><article-title>The first two cases of 2019-nCoV in Italy: Where they come from?</article-title><source>J. Med. Virol.</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25699</pub-id><?supplied-pmid 32022275?><pub-id pub-id-type="pmid">32022275</pub-id></element-citation></ref><ref id="B37-ijms-21-03622"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angeletti</surname><given-names>S.</given-names></name><name><surname>Benvenuto</surname><given-names>D.</given-names></name><name><surname>Bianchi</surname><given-names>M.</given-names></name><name><surname>Giovanetti</surname><given-names>M.</given-names></name><name><surname>Pascarella</surname><given-names>S.</given-names></name><name><surname>Ciccozzi</surname><given-names>M.</given-names></name></person-group><article-title>COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis</article-title><source>J. Med. Virol.</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25719</pub-id></element-citation></ref><ref id="B38-ijms-21-03622"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostini</surname><given-names>M.L.</given-names></name><name><surname>Andres</surname><given-names>E.L.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Graham</surname><given-names>R.L.</given-names></name><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Smith</surname><given-names>E.C.</given-names></name><name><surname>Case</surname><given-names>J.B.</given-names></name><name><surname>Feng</surname><given-names>J.Y.</given-names></name><name><surname>Jordan</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease</article-title><source>MBio</source><year>2018</year><pub-id pub-id-type="doi">10.1128/mBio.00221-18</pub-id></element-citation></ref><ref id="B39-ijms-21-03622"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T.P.</given-names></name><name><surname>Sims</surname><given-names>A.C.</given-names></name><name><surname>Leist</surname><given-names>S.R.</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A.</given-names></name><name><surname>Won</surname><given-names>J.</given-names></name><name><surname>Brown</surname><given-names>A.J.</given-names></name><name><surname>Montgomery</surname><given-names>S.A.</given-names></name><name><surname>Hogg</surname><given-names>A.</given-names></name><name><surname>Babusis</surname><given-names>D.</given-names></name><name><surname>Clarke</surname><given-names>M.O.</given-names></name><etal/></person-group><article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title><source>Nat. Commun.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41467-019-13940-6</pub-id></element-citation></ref><ref id="B40-ijms-21-03622"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>M.L.</given-names></name><name><surname>DeBolt</surname><given-names>C.</given-names></name><name><surname>Lindquist</surname><given-names>S.</given-names></name><name><surname>Lofy</surname><given-names>K.H.</given-names></name><name><surname>Wiesman</surname><given-names>J.</given-names></name><name><surname>Bruce</surname><given-names>H.</given-names></name><name><surname>Spitters</surname><given-names>C.</given-names></name><name><surname>Ericson</surname><given-names>K.</given-names></name><name><surname>Wilkerson</surname><given-names>S.</given-names></name><name><surname>Tural</surname><given-names>A.</given-names></name><etal/></person-group><article-title>First case of 2019 novel coronavirus in the United States</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi">10.1056/NEJMoa2001191</pub-id></element-citation></ref><ref id="B41-ijms-21-03622"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Cao</surname><given-names>R.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Xiao</surname><given-names>G.</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res.</source><year>2020</year><volume>30</volume><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="B42-ijms-21-03622"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Xiang</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China</article-title><source>JAMA J. Am. Med. Assoc.</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id></element-citation></ref><ref id="B43-ijms-21-03622"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.M.</given-names></name><name><surname>Xu</surname><given-names>J.Y.</given-names></name><name><surname>Cao</surname><given-names>B.</given-names></name></person-group><article-title>Potential antiviral therapeutics for 2019 Novel Coronavirus</article-title><source>Zhonghua Jie He He Hu Xi Za Zhi</source><year>2020</year><pub-id pub-id-type="doi">10.3760/cma.j.issn.1001-0939.2020.03.004</pub-id></element-citation></ref><ref id="B44-ijms-21-03622"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Savarino</surname><given-names>A.</given-names></name><name><surname>Boelaert</surname><given-names>J.R.</given-names></name><name><surname>Cassone</surname><given-names>A.</given-names></name><name><surname>Majori</surname><given-names>G.</given-names></name><name><surname>Cauda</surname><given-names>R.</given-names></name></person-group><article-title>Effects of chloroquine on viral infections: An old drug against today&#x02019;s diseases?</article-title><source>Lancet Infect. Dis.</source><year>2003</year><volume>3</volume><fpage>722</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(03)00806-5</pub-id><pub-id pub-id-type="pmid">14592603</pub-id></element-citation></ref><ref id="B45-ijms-21-03622"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>M.J.</given-names></name><name><surname>Bergeron</surname><given-names>E.</given-names></name><name><surname>Benjannet</surname><given-names>S.</given-names></name><name><surname>Erickson</surname><given-names>B.R.</given-names></name><name><surname>Rollin</surname><given-names>P.E.</given-names></name><name><surname>Ksiazek</surname><given-names>T.G.</given-names></name><name><surname>Seidah</surname><given-names>N.G.</given-names></name><name><surname>Nichol</surname><given-names>S.T.</given-names></name></person-group><article-title>Chloroquine is a potent inhibitor of SARS coronavirus infection and spread</article-title><source>Virol. J.</source><year>2005</year><pub-id pub-id-type="doi">10.1186/1743-422X-2-69</pub-id><?supplied-pmid 16115318?><pub-id pub-id-type="pmid">16115318</pub-id></element-citation></ref><ref id="B46-ijms-21-03622"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casorla-P&#x000e9;rez</surname><given-names>L.A.</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>T.</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>S.</given-names></name><name><surname>Arias</surname><given-names>C.F.</given-names></name></person-group><article-title>The Ubiquitin-Proteasome System Is Necessary for Efficient Replication of Human Astrovirus</article-title><source>J. Virol.</source><year>2017</year><pub-id pub-id-type="doi">10.1128/JVI.01809-17</pub-id><?supplied-pmid 29093085?><pub-id pub-id-type="pmid">29093085</pub-id></element-citation></ref><ref id="B47-ijms-21-03622"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>M.</given-names></name><name><surname>Ackermann</surname><given-names>K.</given-names></name><name><surname>Stuart</surname><given-names>M.</given-names></name><name><surname>Wex</surname><given-names>C.</given-names></name><name><surname>Protzer</surname><given-names>U.</given-names></name><name><surname>Sch&#x000e4;tzl</surname><given-names>H.M.</given-names></name><name><surname>Gilch</surname><given-names>S.</given-names></name></person-group><article-title>Severe Acute Respiratory Syndrome Coronavirus Replication Is Severely Impaired by MG132 due to Proteasome-Independent Inhibition of M-Calpain</article-title><source>J. Virol.</source><year>2012</year><pub-id pub-id-type="doi">10.1128/JVI.01001-12</pub-id></element-citation></ref><ref id="B48-ijms-21-03622"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barretto</surname><given-names>N.</given-names></name><name><surname>Jukneliene</surname><given-names>D.</given-names></name><name><surname>Ratia</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Mesecar</surname><given-names>A.D.</given-names></name><name><surname>Baker</surname><given-names>S.C.</given-names></name></person-group><article-title>The Papain-Like Protease of Severe Acute Respiratory Syndrome Coronavirus Has Deubiquitinating Activity</article-title><source>J. Virol.</source><year>2005</year><pub-id pub-id-type="doi">10.1128/JVI.79.24.15189-15198.2005</pub-id></element-citation></ref><ref id="B49-ijms-21-03622"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindner</surname><given-names>H.A.</given-names></name><name><surname>Fotouhi-Ardakani</surname><given-names>N.</given-names></name><name><surname>Lytvyn</surname><given-names>V.</given-names></name><name><surname>Lachance</surname><given-names>P.</given-names></name><name><surname>Sulea</surname><given-names>T.</given-names></name><name><surname>Menard</surname><given-names>R.</given-names></name></person-group><article-title>The Papain-Like Protease from the Severe Acute Respiratory Syndrome Coronavirus Is a Deubiquitinating Enzyme</article-title><source>J. Virol.</source><year>2005</year><pub-id pub-id-type="doi">10.1128/JVI.79.24.15199-15208.2005</pub-id></element-citation></ref><ref id="B50-ijms-21-03622"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibullo</surname><given-names>D.</given-names></name><name><surname>Barbagallo</surname><given-names>I.</given-names></name><name><surname>Giallongo</surname><given-names>C.</given-names></name><name><surname>Vanella</surname><given-names>L.</given-names></name><name><surname>Conticello</surname><given-names>C.</given-names></name><name><surname>Romano</surname><given-names>A.</given-names></name><name><surname>Saccone</surname><given-names>S.</given-names></name><name><surname>Godos</surname><given-names>J.</given-names></name><name><surname>Di Raimondo</surname><given-names>F.</given-names></name><name><surname>Li Volti</surname><given-names>G.</given-names></name></person-group><article-title>Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells</article-title><source>Oncotarget</source><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.7563</pub-id></element-citation></ref><ref id="B51-ijms-21-03622"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>G.</given-names></name><name><surname>Luo</surname><given-names>H.</given-names></name></person-group><article-title>The ubiquitin-proteasome pathway in viral infections</article-title><source>Can. J. Physiol. Pharmacol.</source><year>2006</year><volume>84</volume><fpage>5</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1139/y05-144</pub-id><pub-id pub-id-type="pmid">16845885</pub-id></element-citation></ref><ref id="B52-ijms-21-03622"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tibullo</surname><given-names>D.</given-names></name><name><surname>Longo</surname><given-names>A.</given-names></name><name><surname>Vicario</surname><given-names>N.</given-names></name><name><surname>Romano</surname><given-names>A.</given-names></name><name><surname>Barbato</surname><given-names>A.</given-names></name><name><surname>Rosa</surname><given-names>M.D.</given-names></name><name><surname>Barbagallo</surname><given-names>I.</given-names></name><name><surname>Anfuso</surname><given-names>C.D.</given-names></name><name><surname>Lupo</surname><given-names>G.</given-names></name><name><surname>Gulino</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>323</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12020323</pub-id></element-citation></ref><ref id="B53-ijms-21-03622"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study</article-title><source>J. Chem. Inf. Model.</source><year>2020</year><pub-id pub-id-type="doi">10.1021/acs.jcim.0c00179</pub-id></element-citation></ref><ref id="B54-ijms-21-03622"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moutzouris</surname><given-names>J.P.</given-names></name><name><surname>Che</surname><given-names>W.</given-names></name><name><surname>Ramsay</surname><given-names>E.E.</given-names></name><name><surname>Manetsch</surname><given-names>M.</given-names></name><name><surname>Alkhouri</surname><given-names>H.</given-names></name><name><surname>Bjorkman</surname><given-names>A.M.</given-names></name><name><surname>Schuster</surname><given-names>F.</given-names></name><name><surname>Ge</surname><given-names>Q.</given-names></name><name><surname>Ammit</surname><given-names>A.J.</given-names></name></person-group><article-title>Proteasomal inhibition upregulates the endogenous MAPK deactivator MKP-1 in human airway smooth muscle: Mechanism of action and effect on cytokine secretion</article-title><source>Biochim. Biophys. Acta Mol. Cell Res.</source><year>2010</year><pub-id pub-id-type="doi">10.1016/j.bbamcr.2009.12.007</pub-id><?supplied-pmid 20043958?><pub-id pub-id-type="pmid">20043958</pub-id></element-citation></ref><ref id="B55-ijms-21-03622"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G.-Y.</given-names></name><name><surname>Lai</surname><given-names>M.M.C.</given-names></name></person-group><article-title>The Ubiquitin-Proteasome System Facilitates the Transfer of Murine Coronavirus from Endosome to Cytoplasm during Virus Entry</article-title><source>J. Virol.</source><year>2005</year><pub-id pub-id-type="doi">10.1128/JVI.79.1.644-648.2005</pub-id><?supplied-pmid 15596861?><pub-id pub-id-type="pmid">15596861</pub-id></element-citation></ref><ref id="B56-ijms-21-03622"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>Y.</given-names></name><name><surname>Tanaka</surname><given-names>N.</given-names></name><name><surname>Tanaka</surname><given-names>Y.</given-names></name><name><surname>Inoue</surname><given-names>S.</given-names></name><name><surname>Morita</surname><given-names>K.</given-names></name><name><surname>Zhuang</surname><given-names>M.</given-names></name><name><surname>Hattori</surname><given-names>T.</given-names></name><name><surname>Sugamura</surname><given-names>K.</given-names></name></person-group><article-title>Clathrin-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus into Target Cells Expressing ACE2 with the Cytoplasmic Tail Deleted</article-title><source>J. Virol.</source><year>2007</year><pub-id pub-id-type="doi">10.1128/JVI.00253-07</pub-id><?supplied-pmid 17522231?><pub-id pub-id-type="pmid">17522231</pub-id></element-citation></ref><ref id="B57-ijms-21-03622"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlman</surname><given-names>S.</given-names></name><name><surname>Netland</surname><given-names>J.</given-names></name></person-group><article-title>Coronaviruses post-SARS: Update on replication and pathogenesis</article-title><source>Nat. Rev. Microbiol.</source><year>2009</year><volume>7</volume><fpage>439</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2147</pub-id><pub-id pub-id-type="pmid">19430490</pub-id></element-citation></ref><ref id="B58-ijms-21-03622"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Rao</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name></person-group><article-title>Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2</article-title><source>Virus Res.</source><year>2008</year><pub-id pub-id-type="doi">10.1016/j.virusres.2008.03.004</pub-id></element-citation></ref><ref id="B59-ijms-21-03622"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z.-Y.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Ganesh</surname><given-names>L.</given-names></name><name><surname>Leung</surname><given-names>K.</given-names></name><name><surname>Kong</surname><given-names>W.-P.</given-names></name><name><surname>Schwartz</surname><given-names>O.</given-names></name><name><surname>Subbarao</surname><given-names>K.</given-names></name><name><surname>Nabel</surname><given-names>G.J.</given-names></name></person-group><article-title>pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGN</article-title><source>J. Virol.</source><year>2004</year><pub-id pub-id-type="doi">10.1128/JVI.78.11.5642-5650.2004</pub-id></element-citation></ref><ref id="B60-ijms-21-03622"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satija</surname><given-names>N.</given-names></name><name><surname>Lal</surname><given-names>S.K.</given-names></name></person-group><article-title>The molecular biology of SARS coronavirus</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2007</year><volume>1102</volume><fpage>26</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1196/annals.1408.002</pub-id><pub-id pub-id-type="pmid">17470909</pub-id></element-citation></ref><ref id="B61-ijms-21-03622"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Y.J.</given-names></name><name><surname>Lim</surname><given-names>S.G.</given-names></name><name><surname>Hong</surname><given-names>W.</given-names></name></person-group><article-title>Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus</article-title><source>Antivir. Res.</source><year>2006</year><volume>72</volume><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2006.05.010</pub-id><pub-id pub-id-type="pmid">16820226</pub-id></element-citation></ref><ref id="B62-ijms-21-03622"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Ivanov</surname><given-names>K.A.</given-names></name><name><surname>Putics</surname><given-names>&#x000c1;.</given-names></name><name><surname>Hertzig</surname><given-names>T.</given-names></name><name><surname>Schelle</surname><given-names>B.</given-names></name><name><surname>Bayer</surname><given-names>S.</given-names></name><name><surname>Wei&#x000df;brich</surname><given-names>B.</given-names></name><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>Rabenau</surname><given-names>H.</given-names></name><name><surname>Doerr</surname><given-names>H.W.</given-names></name><etal/></person-group><article-title>Mechanisms and enzymes involved in SARS coronavirus genome expression</article-title><source>J. Gen. Virol.</source><year>2003</year><volume>84</volume><fpage>2305</fpage><lpage>2315</lpage><pub-id pub-id-type="doi">10.1099/vir.0.19424-0</pub-id><pub-id pub-id-type="pmid">12917450</pub-id></element-citation></ref><ref id="B63-ijms-21-03622"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>van der Meer</surname><given-names>Y.</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>J.</given-names></name><name><surname>Onderwater</surname><given-names>J.J.M.</given-names></name><name><surname>van der Meulen</surname><given-names>J.</given-names></name><name><surname>Koerten</surname><given-names>H.K.</given-names></name><name><surname>Mommaas</surname><given-names>A.M.</given-names></name></person-group><article-title>Ultrastructure and Origin of Membrane Vesicles Associated with the Severe Acute Respiratory Syndrome Coronavirus Replication Complex</article-title><source>J. Virol.</source><year>2006</year><pub-id pub-id-type="doi">10.1128/JVI.02501-05</pub-id></element-citation></ref><ref id="B64-ijms-21-03622"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klumperman</surname><given-names>J.</given-names></name><name><surname>Locker</surname><given-names>J.K.</given-names></name><name><surname>Meijer</surname><given-names>A.</given-names></name><name><surname>Horzinek</surname><given-names>M.C.</given-names></name><name><surname>Geuze</surname><given-names>H.J.</given-names></name><name><surname>Rottier</surname><given-names>P.J.</given-names></name></person-group><article-title>Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding</article-title><source>J. Virol.</source><year>1994</year><pub-id pub-id-type="doi">10.1128/JVI.68.10.6523-6534.1994</pub-id></element-citation></ref><ref id="B65-ijms-21-03622"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stertz</surname><given-names>S.</given-names></name><name><surname>Reichelt</surname><given-names>M.</given-names></name><name><surname>Spiegel</surname><given-names>M.</given-names></name><name><surname>Kuri</surname><given-names>T.</given-names></name><name><surname>Mart&#x000ed;nez-Sobrido</surname><given-names>L.</given-names></name><name><surname>Garc&#x000ed;a-Sastre</surname><given-names>A.</given-names></name><name><surname>Weber</surname><given-names>F.</given-names></name><name><surname>Kochs</surname><given-names>G.</given-names></name></person-group><article-title>The intracellular sites of early replication and budding of SARS-coronavirus</article-title><source>Virology</source><year>2007</year><pub-id pub-id-type="doi">10.1016/j.virol.2006.11.027</pub-id><?supplied-pmid 17210170?><pub-id pub-id-type="pmid">17210170</pub-id></element-citation></ref><ref id="B66-ijms-21-03622"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raaben</surname><given-names>M.</given-names></name><name><surname>Posthuma</surname><given-names>C.C.</given-names></name><name><surname>Verheije</surname><given-names>M.H.</given-names></name><name><surname>te Lintelo</surname><given-names>E.G.</given-names></name><name><surname>Kikkert</surname><given-names>M.</given-names></name><name><surname>Drijfhout</surname><given-names>J.W.</given-names></name><name><surname>Snijder</surname><given-names>E.J.</given-names></name><name><surname>Rottier</surname><given-names>P.J.M.</given-names></name><name><surname>de Haan</surname><given-names>C.A.M.</given-names></name></person-group><article-title>The Ubiquitin-Proteasome System Plays an Important Role during Various Stages of the Coronavirus Infection Cycle</article-title><source>J. Virol.</source><year>2010</year><pub-id pub-id-type="doi">10.1128/JVI.00485-10</pub-id><?supplied-pmid 20484504?><pub-id pub-id-type="pmid">20484504</pub-id></element-citation></ref><ref id="B67-ijms-21-03622"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisselev</surname><given-names>A.F.</given-names></name><name><surname>Goldberg</surname><given-names>A.L.</given-names></name></person-group><article-title>Proteasome inhibitors: From research tools to drug candidates</article-title><source>Chem. Biol.</source><year>2001</year><volume>8</volume><fpage>739</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(01)00056-4</pub-id><pub-id pub-id-type="pmid">11514224</pub-id></element-citation></ref><ref id="B68-ijms-21-03622"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>A.M.</given-names></name><name><surname>Seth</surname><given-names>A.K.</given-names></name></person-group><article-title>The ubiquitin-mediated protein degradation pathway in cancer: Therapeutic implications</article-title><source>Eur. J. Cancer</source><year>2004</year><pub-id pub-id-type="doi">10.1016/j.ejca.2004.07.006</pub-id></element-citation></ref><ref id="B69-ijms-21-03622"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>L.</given-names></name><name><surname>Mohan</surname><given-names>R.</given-names></name><name><surname>Kwok</surname><given-names>B.H.B.</given-names></name><name><surname>Elofsson</surname><given-names>M.</given-names></name><name><surname>Sin</surname><given-names>N.</given-names></name><name><surname>Crews</surname><given-names>C.M.</given-names></name></person-group><article-title>Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1999</year><pub-id pub-id-type="doi">10.1073/pnas.96.18.10403</pub-id></element-citation></ref><ref id="B70-ijms-21-03622"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrowska</surname><given-names>H.</given-names></name><name><surname>Wojcik</surname><given-names>C.</given-names></name><name><surname>Omura</surname><given-names>S.</given-names></name><name><surname>Worowski</surname><given-names>K.</given-names></name></person-group><article-title>Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1997</year><pub-id pub-id-type="doi">10.1006/bbrc.1997.6434</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-21-03622-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(<bold>A</bold>) Structure of the coronavirus. (<bold>B</bold>) The 7 Coronaviruses known to infect humans.</p></caption><graphic xlink:href="ijms-21-03622-g001"/></fig><fig id="ijms-21-03622-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Chemical structures of several proteasome inhibitors. In yellow circle the subunit target of the drugs. Pubchem.</p></caption><graphic xlink:href="ijms-21-03622-g002"/></fig><fig id="ijms-21-03622-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>A schematic representation of the possible mechanism of proteasome inhibitors in virus replication.</p></caption><graphic xlink:href="ijms-21-03622-g003"/></fig></floats-group></article>